Biopharmaceutical Industry Market Research Reports, May 2013

Import (harmonized System): Nucleic Acids And Their Salts, Other Heterocyclic Compounds

• Industry data
• April 2013

Monthly, From 2009 To 2013
Source: U.S. Department of Labor: Bureau of Labor Statistics

• Industries : Biopharmaceutical
• Countries : United States

Company Report: Biopharmaceutical in Japan and France for Year 2012

• Company report
• December 2012
• 5 pages
• by Governmental Agency

• Industries: Biopharmaceutical
• Countries: Japan, France

Company Report: Enzyme in Netherlands and China for Year 2012

• Company report
• December 2012
• 27 pages
• by Corporation

... Reaction require less raw materials reduce waste and energy consumption save cost in a sustainable way slide 8 primary food production a.O. enzymes, cultures food manufacturing retail & catering end ...

• Industries: Biopharmaceutical
• Countries: World, Netherlands, China

Pfizer Inc. - Company Report for Year 2012

• Company report
• December 2012
• 269 pages

... To as Follow-on biologics ). Such biosimilars would reference biotechnology products approved under the u.S. Public health service act. Additionally, the fda has approved a biosimilar recombinant human growth ...

• Industries: Biopharmaceutical
• Countries: United States

Investor presentation: Biopharmaceutical in Canada for Year 2012

• Company report
• December 2012
• 37 pages

... Clinical researc tria esign assistance Waiver of prescription drug user fees. Type 1 plasminogen deficiency Plasminogen: plasminogen is a naturally occurring protein synthesized by the liver ...

• Industries: Biopharmaceutical
• Countries: Canada

Company Report: Biopharmaceutical in Belgium for Year 2012

• Company report
• November 2012
• 4 pages

... Virus that infects the lungs and respiratory tract about ablynx ablynx is a biopharmaceutical company engaged in the discovery and development of nanobodies , a novel class of therapeutic proteins ...

• Industries: Biopharmaceutical
• Countries: Belgium

Company Report: Biopharmaceutical in Belgium for Year 2012

• Company report
• November 2012
• 3 pages
• by Corporation

... In the biopharmaceutical sector. In order to achieve this goal, the strong partnership that exists between the government and the industry needs to be maintained. In this spirit, the government has proposed to set up five ...

• Industries: Biopharmaceutical
• Countries: Belgium

Repligen Corp. - Annual Report 2012

• Company report
• November 2012
• 96 pages

... That are not measured at fair value on a recurring basis. 8. Inventories inventories relate to the company s bioprocessing business. The company values inventory at cost or, if lower, fair market value using the first ...

• Industries: Biopharmaceutical
• Countries: United States, Sweden

MorphoSys AG - Company Report for Year 2012

• Company report
• November 2012
• 19 pages

... Of going into even earlier- stage suffes. We also believe that gantenerumab has better properties than solanezumab, in that our antibody was deliberately made to bind and break down amyloid oligomers ...

• Industries: Biopharmaceutical

Company Report: Biopharmaceutical in Germany, Austria and Switzerland for Year 2012

• Company report
• November 2012
• 3 pages

... Represented by its new brand boehringer ingelheim bioxcellence . As a leading biopharmaceutical contract manufactu with more than 35 years of experience The company has brought 19 biopharmaceutical ...

• Industries: Biopharmaceutical
• Countries: Germany, Austria, Switzerland

Company Report: Biopharmaceutical in Japan and France for Year 2013

• Company report
• January 2013
• 2 pages

... Stem cells, to pharmaceutical and biotechnology companies for the production of therapeutic and prophylactic viral vaccines, virosomes, vlps and recombinant proteins, including monoclonal antibodies ...

• Industries: Biopharmaceutical
• Countries: Japan, France

Biocon Ltd. - Company Report for Year 2013

• Company report
• January 2013
• 2 pages
• by Corporation

• Industries: Biopharmaceutical
• Countries: India, Singapore

Intercell AG - Company Report for Year 2013

• Company report
• May 2013
• 4 pages

... And production of rare, fully human monoclonal antibodies are offered by vivalis. Through these programs, vivalis receives payments associated with the funding of discovery research, an upfront payment, clinical ...

• Industries: Biopharmaceutical
• Countries: United States, Japan, France

Company Report: Protein in The United States for Year 2013

• Company report
• May 2013
• 11 pages

... Therapeutics for folding diseases or folding solutions are difficult to develop because proteins are moving targets }disease or misfolding n o ye s -high throughput readout signal -- yes/no decrease ...

• Industries: Biopharmaceutical
• Countries: United States

New Enterprise Associates - Company Report for Year 2013

• Company report
• April 2013
• 3 pages

• Industries: Biopharmaceutical
• Countries: United States

Company Report: Biopharmaceutical in The United States for Year 2013

• Company report
• March 2013
• 28 pages

• Industries: Biopharmaceutical
• Countries: United States

Company Report: Biopharmaceutical in Israel and The United States for Year 2013

• Company report
• February 2013
• 11 pages
• by Corporation

• Industries: Biopharmaceutical
• Countries: Israel, United States

Company Report: Vaccine in Canada for Year 2013

• Company report
• February 2013
• 2 pages

• Industries: Biopharmaceutical
• Countries: Canada

Enzyme Sector Analysis

• Industry report
• March 2013
• 90 pages

... Production Preparation of enzymes 21/03/2013 why enzymes Catalysts increase the rate of reactions without any net change in their structure. Concept of catalysis is developed as early as the 19th ...

• Industries: Biopharmaceutical

Biosimilar Market Analysis in The United States and Japan

• Industry report
• May 2013
• 62 pages

... Be treated as a unique entity diclofenac = monoclonal antibodies shown within the circles: the reference product and each biosimilar has different post-translational modifications (in this case ...

• Industries: Biopharmaceutical
• Countries: United States, Japan

The Norwegian Protein Sector Brief (protein, enzyme product)

• Industry report
• November 2012
• 11 pages

... Of 12,500 mt ~40% Output final products Long term agreements for raw material supply Key objective to provide high value added biomarine ingredients to serve a growing demand of high grade protein ...

• Industries: Biopharmaceutical
• Countries: Norway

Biopharmaceutical Sector in The United Kingdom

• Industry report
• November 2012
• 24 pages
• by Research Paper

• Industries: Biopharmaceutical
• Countries: United Kingdom

The German Biopharmaceutical Business

• Industry report
• February 2013
• 32 pages

... But this system lacks mechanisms to carry out posttranslational modifications. Today, plants represent an alternative for production of recombinant proteins. As bioreactors, they offer the possibility ...

• Industries: Biopharmaceutical
• Countries: Germany

U.S. Antibody Industry Brief

• Industry report
• April 2013
• 15 pages

... Selection antibody generation assay development cell line development bio-analytical assay development manufacturing research process optimization product positioning research poc studies additional ...

• Industries: Biopharmaceutical
• Countries: United States

Biosimilar in The United States : Innovation and Technology Trends (biosimilar, monoclonal antibody)

• Industry report
• November 2012
• 35 pages

... Sandoz analysis rising demand and high cost of biologics will continue to strain shrinking health care budgetsgg biologics contribute to increased costs worldwide biosimilars are expected to relieve ...

• Industries: Biopharmaceutical
• Countries: World, United States

The British Biopharmaceutical Business : Innovation and Technology Trends

• Industry report
• December 2012
• 33 pages

... Eurostars tsb national- sbri, ktp, biomedical catalyst devolved administration/regional funding- manufacturing advisor service (mas) t e c h n o lo g y r e a d in e s s l e v e l (t r l ) t e c h n o lo g ...

• Industries: Biopharmaceutical
• Countries: United Kingdom

The Danish Enzyme Sector

• Industry report
• December 2012
• 30 pages

... Method that may reduce the amount of enzyme used and increase enzymatic productivity is to recycle the enzymes [10,11]. Conceptually, the assumption is that by recovering the active enzymes from ...

• Industries: Biopharmaceutical
• Countries: Denmark

Vaccine Market Statistics in The United States and Canada

• Industry report
• February 2013
• 37 pages

• Industries: Biopharmaceutical
• Countries: United States, Canada

The South Korean Bioprocessing Industry Brief (bioprocessing, biosimilar)

• Industry report
• April 2013
• 8 pages

... Innovation in biologics will be the theme of this meeting. Among the biologic drug cands, monoclonal antibody (mab) is the fastest growing area of global pharmaceutical market. Mab is set to lead ...

• Industries: Biopharmaceutical
• Countries: South Korea

The Swedish Protein Industry Brief

• Industry report
• January 2013
• 16 pages
• by Research Paper

... On accumulation of wheat grain proteins. J. Sci. Food agri. 91, 2192-2200. Malik, a. H., Kuktaite, r., Johansson, e. 2013. Accumulation of proteins in the wheat grain: the com- bined effect of genetic ...

• Industries: Cereal Production, Biopharmaceutical
• Countries: Sweden

The Indian Enzyme Industry Brief (enzyme, protein)

• Industry report
• March 2013
• 8 pages
• by Corporation

... Accounts for 10% of the global scenario [29]. The demand of diagnostic and therapeutic enzymes is expected to increase owing to improvement in medical care facilities in developing countries and global ...

• Industries: Biopharmaceutical
• Countries: India